RITA - a small-molecule anticancer drug that targets p53

被引：13

作者：

Doggrell, SA ^{[1
]}

机构：

[1] Auckland Univ Technol, Auckland, New Zealand

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期

关键词：

colon cancer; immunodeficient mice; NSC-652287; p53; RITA; tumour cell lines;

D O I：

10.1517/13543784.14.6.739

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The first tumour-suppressor gene to be identified was p53. Reactivation of p53 and induction of tumour cell apoptosis (RITA) is a small molecule that inhibits the growth of a wild-type p53 colon carcinoma cell line with minimal effect on a cell line without the wild-type p53. RITA increased p53 in human tumour cell lines that expressed wild-type p53 (colon, osteosarcoma and fibrosarcoma cells). This was due to an increased half-life of RITA. in immunodeficient mice, RITA 0.1 mg/kg i.p. for 5 days suppressed the growth of the wild-type p53 colon carcinoma tumour by 40% without any apparent effect on the tumour without the wild-type p53. The development of RITA for the treatment of wild-type p53-containing cancers should continue.

引用

收藏

页码：739 / 742

页数：4

相关论文

共 8 条

[1] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].

Chène, P .

NATURE REVIEWS CANCER, 2003, 3 (02) :102-109

[2] Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors [J].

Issaeva, N ;

Bozko, P ;

Enge, M ;

Protopopova, M ;

Verhoef, LGGC ;

Masucci, M ;

Pramanik, A ;

Selivanova, G .

NATURE MEDICINE, 2004, 10 (12) :1321-1328

[3] Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors [J].

Lai, ZH ;

Yang, T ;

Kim, YB ;

Sielecki, TM ;

Diamond, MA ;

Strack, P ;

Rolfe, M ;

Caligiuri, M ;

Benfield, PA ;

Auger, KR ;

Copeland, RA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) :14734-14739

[4] DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells [J].

Nieves-Neira, W ;

Rivera, MI ;

Kohlhagen, G ;

Hursey, ML ;

Pourquier, P ;

Sausville, EA ;

Pommier, Y .

MOLECULAR PHARMACOLOGY, 1999, 56 (03) :478-484

[5] Selective toxicity of the tricyclic thiophene NSC652287 in renal carcinoma cell lines - Differential accumulation and metabolism [J].

Rivera, MI ;

Stinson, SF ;

Vistica, DT ;

Jorden, JL ;

Kenney, S ;

Sausville, EA .

BIOCHEMICAL PHARMACOLOGY, 1999, 57 (11) :1283-1295

[6] In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 [J].

Vassilev, LT ;

Vu, BT ;

Graves, B ;

Carvajal, D ;

Podlaski, F ;

Filipovic, Z ;

Kong, N ;

Kammlott, U ;

Lukacs, C ;

Klein, C ;

Fotouhi, N ;

Liu, EA .

SCIENCE, 2004, 303 (5659) :844-848

[7] Surfing the p53 network [J].

Vogelstein, B ;

Lane, D ;

Levine, AJ .

NATURE, 2000, 408 (6810) :307-310

[8] The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure [J].

Zhao, JH ;

Wang, MJ ;

Chen, J ;

Luo, AP ;

Wang, XQ ;

Wu, M ;

Yin, DL ;

Liu, ZH .

CANCER LETTERS, 2002, 183 (01) :69-77